These medications include tamoxifen and differ from hormone ... hormone therapy and drugs targeting HER2 may help treat triple-positive breast cancer. Other treatments may include surgery ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Atossa Therapeutics (ATOS) announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes ...